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Background: Reimbursement policies for anti-cancer drugs vary among countries even though they rely on the
same clinical evidence. We compared the pattern of publicly funded drug programs and analyzed major factors
influencing the differences.
Methods: We investigated reimbursement policies for 19 indications with targeted anti-cancer drugs that are used
variably across ten countries. The available incremental cost-effectiveness ratio (ICER) data were retrieved for each
indication. Based on the comparison between actual reimbursement decisions and the ICERs, we formulated a
reimbursement adequacy index (RAI): calculating the proportion of cost-effective decisions, either reimbursement of
cost-effective indications or non-reimbursement of cost-ineffective indications, out of the total number of indications
for each country. The relationship between RAI and other indices were analyzed, including governmental dependency
on health technology assessment, as well as other parameters for health expenditure. All the data used in this study
were gathered from sources publicly available online.
Results: Japan and France were the most likely to reimburse indications (16/19), whereas Sweden and the United
Kingdom were the least likely to reimburse them (5/19 and 6/19, respectively). Indications with high cost-effectiveness
values were more likely to be reimbursed (ρ = −0.68, P = 0.001). The three countries with high RAI scores each had a
healthcare system that was financed by general taxation.
Conclusions: Although reimbursement policies for anti-cancer drugs vary among countries, we found a strong
correlation of reimbursements for those indications with lower ICERs. Countries with healthcare systems financed by
general taxation demonstrated greater cost-effectiveness as evidenced by reimbursement decisions of anti-cancer
drugs.
Keywords: Anti-cancer drugs, Reimbursement, Cost-effectivenessBackground
Each country has limited financial resources devoted to
public healthcare; thus, how to best allocate these finite
resources in an efficient and justifiable way poses a great
challenge at the national level. Especially, expenditure
on cancer drugs imposes substantial burdens on patients
and providers of health insurance in all countries [1-4].
The costs of cancer drugs have arisen concurrently with
the shift from conventional cytotoxic drugs to targeted* Correspondence: heo1013@snu.ac.kr
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unless otherwise stated.therapies, including monoclonal antibodies and tyrosine
kinase inhibitors, in the application of new drugs for
cancer treatment [5,6].
Considering that many new anti-cancer drugs are used
to provide modest survival benefits and sometimes solely
for the purpose of palliative treatment, cost-effectiveness
must be addressed in addition to clinical efficacy [7,8].
For example, Moore et al. reported a statistically signifi-
cant survival benefit of 0.33 months (6.24 vs. 5.91 months)
for erlotinib plus gemcitabine compared to gemcitabine
alone for first-line treatment of advanced pancreatic can-
cer [9]. However, the result of this finding regarding the
value of erlotinib’s small survival benefit has been contro-
versial; the question remains whether we should pay for a
drug that improves survival by a median of 10 days with. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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$500,000 per year of life saved [8]. To provide guidelines
for such kinds of questions, many countries have adopted
evidence-based health technology assessment (HTA) pro-
grams that analyze the clinical and cost-effectiveness of se-
lected medical technologies to serve as part of the basis
for their recommendations [3,10-12]. Using their national
assessment programs, France, Germany, and the United
Kingdom (UK) have decided not to reimburse erlotinib
for first-line treatment of advanced pancreatic cancer,
whereas Korea, Japan, and the United States (US) have
chosen to reimburse this indication.
As mentioned above, it is noteworthy that even with
the same clinical evidence for anti-cancer drugs, reim-
bursement policies vary among countries [13] because
the criteria of cost-effectiveness and additional costs are
country-specific and difficult to standardize [14]. The goal
of this study was to compare the pattern of publicly
funded cancer drug programs in ten countries, and to
identify the major factors that explain the differences
according to the perspective of each country’s health care
system.
Methods
Countries and drug indications
For this study, we selected countries that have both
universal health care and national or regional public
drug reimbursement programs funded by general taxation
or premiums. The following ten countries with significant
structural and cultural differences in regards to their
respective health care system were included: Australia,
Canada (Ontario), France, Germany, Japan, Korea, Sweden,
Taiwan, the UK, and the US. All countries except Taiwan
are the Organization for Economic Co-operation and
Development (OECD) member countries; Taiwan was
included to better balance the Eastern and Western
countries selected for this study. The US was included
for comparative purposes, although it has a multi-payer sys-
tem comprised of private insurance and social insurance
programs, with Medicare covering people over 65 years of
age and social welfare programs, such as Medicaid, avail-
able for low-income people. However, it is not the case for
private insurers or indeed for the tens of millions of US citi-
zens that are uninsured. Canada is also unique because
drug reimbursement is the responsibility of each province
and territory. This study chose to include Ontario to repre-
sent Canada, as it is Canada’s most populated province.
In choosing the drugs, we identified molecularly tar-
geted anti-cancer drugs that were approved after 2004
and are variably used in our ten countries of interest.
The following thirteen anti-cancer drugs were selected:
bevacizumab, cetuximab, crizotinib, dasatinib, erlotinib,
imatinib, lapatinib, lenalidomide, nilotinib, pemetrexed,
sorafenib, sunitinib, and temsirolimus. We then selectedtheir 19 indications to ensure coverage of a variety of
both solid and hematologic malignancies, and mechanisms
of action. These indications have evidence of clinical effi-
cacy with modest survival benefit (Table 1) and a resulting
ICER in the range of $15,000 ~ $450,000. Herceptin for
breast cancer, and rituximab for malignant lymphoma were
not included because most countries reimburse both drugs
without much controversy. Some new drugs were excluded,
because they were available only in selected countries.
Reimbursed indications
The approval years of reimbursement for the 13 anti-
cancer drugs were obtained from drug registries of the
following authorities of ten countries (as of February 3,
2013): Australia, Pharmaceutical Benefits Scheme in
consultation with Pharmaceutical Benefits Advisory
Committee (PBAC) [15]; Canada, Ontario Guidelines
for Economic Analysis of Pharmaceutical Products in
consultation with Ministry of Health and Long-Term
Care [16-19]; France, The Haute Autorité de santé in
consultation with the Transparency Comission [20];
Germany, Federal Ministry of Health in consultation
with the Joint Federal Committee (G-BA) [21] and In-
stitute for Quality & Efficiency in Health Care [22];
Japan, The Ministry of Health, Labour and Welfare in
consultation with Chuikyo [23]; Korea, Korea Food &
Drug Administration in consultation with Health In-
surance Review & Assessment Service [24]; Sweden,
Dental and Pharmaceutical Benefits Agency-TLV [25];
Taiwan, Bureau of National Health Insurance in con-
sultation with Drug Beneficiary Committee and Center
for Drug Evaluation [26]; the UK, National Health Ser-
vice in consultation with National Institute for Health
and Care Excellence (NICE) [27]; and the US, Food
and Drug Administration (FDA) [28]. After identifying
insurance coverage data, some of the collected data
were then verified by the health care authorities through
personal email communications.
The term “reimbursement approval year” refers to the
date that the indication was granted reimbursement
authorization by each country’s governmental regulatory
bodies, such as the HTA agencies. In the case of the US,
the date of FDA approval was used. However, it should
be noted that FDA approval for a certain cancer drug
does not necessarily mean that the drug is reimbursed.
The US Centers for Medicare and Medicaid Services
typically include all US FDA-approved medications on
their formulary, through an evidence-based process with-
out the analysis of cost-effectiveness [29]. On the other
hand, private health care plans make formulary decisions
individually and these processes vary widely. Because they
do not make such information available to the public, it
was not possible to find the date of reimbursement that
represented the US as a whole.
Table 1 Reimbursement approval year for indications of 13 anti-cancer drugs in 10 countries (as of February 3, 2013)
Drug Indications Countries
Australia Canada (Ontario) France Germany Japan Korea Sweden Taiwan UK US*
Bevacizumab Colorectal cancer : with irinotecan,
fluorouracil, and leucovorin
No 2009 2005 2009 2007 No No 2011 No 2004
Colorectal cancer : with oxaliplatin,
fluorouracil, and folinic acid
2008 2009 2008 2009 2009 No No No No 2006
NSCLC : 1st line with platinum-based
chemotherapy
No No 2008 2009 2009 No No No No 2006
Renal cell carcinoma : 1st line with
interferon-α
No No 2008 2009 No No No No No 2009
Cetuximab Colorectal cancer : with irinotecan 2010 2011 2009 2009 2008 No No 2009 No 2004
Colorectal cancer (K-RAS wild type):
1st line with oxaliplatin, fluorouracil,
and folinic acid
2010 No 2009 2009 2010 No No No 2009 2012
Head and neck cancer (squamous
cell carcinoma) : 1st line with
platinum-based chemotherapy
2007 2011 2010 No No No No 2009 No 2011
Crizotinib NSCLC (ALK fusion positive): 2nd
line (vs. docetaxel)
No No No No No No No No No 2011
Dasatinib Chronic myeloid leukemia, chronic
phase: 1st line
2009 2008 2007 No 2009 2008 2011 2009 No 2010
Erlotinib Pancreatic cancer : 1st line with
gemcitabine
2012 No No No 2011 2010 No No No 2005
Imatinib Gastrointestinal stromal tumor:
Adjuvant therapy
2011 2008 2009 No No 2010 2009 2011 no 2008
Lapatinib Breast cancer with HER2
overexpression: 2nd line with
capecitabine
No No 2008 No 2009 2010 No No No 2007
Lenalidomide Multiple myeloma : 1st-line No 2009 No No 2010 No 2008 No 2009 2006
Nilotinib Chronic myeloid leukemia, chronic
phase: 1st-line
2011 2012 2008 2011 2010 2011 2008 2012 2012 2007
Pemetrexed NSCLC: Maintenance treatment No 2008 2008 No 2009 No No No 2010 2009
NSCLC (for non-squamous
histology): 1st line with
cisplatin
2009 2008 2008 No 2009 2010 No 2009 2009 2008
Sorafenib Liver cancer : 1st line 2008 2008 2008 2009 2009 2011 No No No 2007
Sunitinib Renal cell carcinoma : 1st line 2010 2008 2006 2009 2008 2007 2006 2010 2009 2006
Temsirolimus Renal cell carcinoma : 1st-line for
poor prognosis patients
No 2011 2008 2009 2010 2011 No No No 2007
Abbreviations: UK United Kingdom, US United States, NSCLC non-small cell lung cancer.
*For United States, Food and Drug Administration (FDA) approval dates are used. However, the fact that FDA approved a certain cancer drug does not mean that
that drug is reimbursed.
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The ICER is commonly used to compare treatments
across various indications in cost-effective analysis. The
ICER is defined as the ratio of additional costs to incre-
mental benefits of a treatment, and is usually measured as
the cost per quality-adjusted life-year (QALY) [30]. The
ICER data for each indication were retrieved from the in-
formation made available by health authorities online.
Social health insurance systems
Social health insurance systems of each country were
categorized in order to see how they correlated withreimbursement decisions regarding expensive anti-cancer
drugs. There are three different types of health care sys-
tems based on who collects and provides health care: 1) A
multi-payer system comprised of the government-run pro-
grams (the dominant insurer) and the private insurances:
the government is neither the main healthcare provider
nor the collector of money for health care. Individuals
have the responsibility to be self-insured; 2) Social health
insurance system: the direct provider of health care is not
the government, but the government has the financial
power to purchase private or public insurance for the
people. The fact that the government plays a critical role
Table 2 An example of the calculation of reimbursement




Reimbursed 3 6 9
Not reimbursed 3 7 10
6 13 19
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sarily mean that the government provides care; and 3)
Publicly funded health system: the government directly
manages and operates facilities for health care and performs
the insurance function of reimbursement. The government
runs the single insurance scheme but does not provide the
care [31].
For the ten countries of interest, the financing systems
were analyzed to determine whether they affected the
reimbursement decision of expensive anti-cancer drugs.
For each country, the HTA authority was identified and
the date of implementation of HTA in the decision mak-
ing process was also noted. The form of health security
was also assessed to categorize countries into different
operation systems: customer sovereignty model, social
health insurance, and national healthcare service. To
estimate the magnitude of expenditure on health care,
we also investigated the health expenditure of ten coun-
tries using data from the OECD [32].
Calculation of reimbursement adequacy index
There are two aspects in assessing the reimbursement
policy of each country. The first aspect considers how
well the policy handles reimbursements for indications
that are considered cost-effective. The second aspect
considers how well the policy does in not reimbursing
indications that are considered cost-ineffective.
In order to assess the cost-effectiveness of reimbursement
decisions for the selected anti-cancer drug indications
across different countries, we applied a statistical method
for measuring the accuracy of diagnostic procedures and
calculated the reimbursement adequacy index (RAI) for
each country as follows. In case of the US, however, we
did not calculate its RAI in that the US has no single dom-
inant health insurance program.
Test outcomes reflect whether an indication is reim-
bursed or not. To determine the condition status, each
indication was assessed to be either cost-effective or
cost-ineffective. Although there is no reliable empirical
basis on deciding cost-effectiveness thresholds in health-
care, WHO considers that technologies for which the
ICER is more than three times a country’s gross domestic
product (GDP) per capita will invariably be cost ineffective
[6,33]. Therefore, the indications with ICERs less than
three times a country’s GDP per capita were considered to
be cost-effective in this study.
RAI is the proportion of cost-effective decisions, either
reimbursement of cost-effective indications or non-reim-
bursement of cost-ineffective indications, out of total
indications.
RAI ¼
number of reimbursed indications that are cost effective þ
number of not reimbursed indications that are cost ineffective
Total number of indicationsFor example, the cost-effective threshold in Korea was
calculated by multiplying Korea’s GDP by 3 ($26881 × 3 =
$80643). Therefore, the indications with ICERs less than
$80643 were considered to be cost-effective. For Korea, a
2 × 2 table was constructed; the columns represent the
condition (cost-effectiveness) and the rows represent the
test outcome (reimbursement decision) (Table 2).
RAI Korea ¼ 3þ 7




We used Spearman’s rank correlation coefficient for
the association between the two variables, and considered
P <0.05 to be statistically significant.
Heatmap plot and clustering
To cluster the countries with distinct characteristics of
reimbursement policies, we used microarray analysis
methods and drew a heatmap plot using MultiExperiment
Viwer (MeV) version 4.7. First, we made a 10 × 19 matrix
(10 countries and 19 indications) based on Table 1. Then,
each indication was sorted from the lowest to highest
ICER. For hierarchical clustering, we used a metric algo-
rithm and an average linkage as a linkage method.
Ethics statement
This study does not involve human subjects, human ma-
terial, or human data, and therefore, does not require
ethics approval. All the data used in this study were
gathered from sources publicly available online.
Results
Reimbursed indications
Table 1 shows the information regarding whether each
country reimburses a certain indication, and if reimbursed,
when each country first approved the reimbursement. Not
counting the US, Japan and France were the most likely to
reimburse the indications (16/19), whereas Sweden and
the UK were the least likely to reimburse them (5/19 and
6/19, respectively).
ICER
The ICER data was available only in two countries: UK
(NICE) and Australia (PBAC). We found NICE to be the
most comprehensive and used the ICER from NICE as
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the data was not otherwise available. If the ICER was
unavailable due to manufacturer’s unwillingness (beva-
cizumab plus platinum-based chemotherapy for advanced
non-small cell lung cancer) [34] or unissued appraisal (er-
lotinib plus gemcitabine for advanced pancreatic cancer),
we retrieved the relevant ICER value from PBAC (bevaci-
zumab) [35] or through a literature review (erlotinib) [8].
Table 3 shows the representative ICER for each drug indi-
cation in the increasing order of ICER values. We found a
strong correlation of reimbursements for indications with
lower ICERs (ρ = −0.68, P = 0.001); the indication with
lower ICER was more likely to be reimbursed (Figure 1).
Social health insurance systems and the reimbursement
adequacy index
Table 4 shows the RAI and social health insurance sys-
tems across the ten countries. The UK had the highest
RAI scores. Four countries with high RAI scores (UK,
Canada, Australia, and Sweden) have health care systems
that are all financed mainly by general taxation. On the
other hand, the three countries with the lowest RAI
scores were Korea, Taiwan, and Germany. In these coun-
tries, the social health insurance is financed by payrollTable 3 Representative incremental cost-effectiveness ratio fo
Drug Indications
Nilotinib Chronic myeloid leukemia, chronic phase: 1st-line
Imatinib Gastrointestinal stromal tumor: Adjuvant therapy
Cetuximab Colorectal cancer (K-RAS wild type): 1st line with o
Pemetrexed NSCLC (for non-squamous histology): 1st line with
Lenalidomide Multiple myeloma: 1st-line
Pemetrexed NSCLC: Maintenance treatment
Sorafenib Liver cancer: 1st line
Sunitinib Renal cell carcinoma: 1st line
Lapatinib Breast cancer with HER2 overexpression: 2nd line w
Bevacizumab Colorectal cancer: with irinotecan, fluorouracil, and
Bevacizumab Colorectal cancer: with oxaliplatin, fluorouracil, and
Dasatinib Chronic myeloid leukemia, chronic phase: 1st-line
Cetuximab Colorectal cancer: with irinotecan
Temsirolimus Renal cell carcinoma: 1st-line for poor prognosis p
Bevacizumab Renal cell carcinoma: 1st line with interferon-α
Crizotinib NSCLC (ALK fusion positive): 2nd line (vs. docetaxe
Bevacizumab NSCLC: 1st line with platinum-based chemotherap
Cetuximab Head and neck cancer (squamous cell carcinoma)
Erlotinib Pancreatic cancer: 1st line with gemcitabine
ICER, Incremental Cost Effectiveness Ratio; NSCLC, non-small cell lung cancer.
*Most ICER values except two indications were retrieved from the National Institute
US dollars; £1 equals $1.574 (as of January 29, 2013)).
†This value was from the Pharmaceutical Benefits Advisory Committee in Australia.
elements/pbac-meetings/psd/2011-03/pbac-psd-bevacizumab-march11.
‡This value was from Miksad RA et al. J Clin Oncol 25:4506–7; author reply 4508, 200tax or premiums rather than general taxation. Interestingly,
countries with high RAI scores (UK, Canada, Australia, and
Sweden) have incorporated HTA since the 1990’s, whereas
countries with low RAI scores (Korea, Taiwan, and
Germany) have only recently incorporated HTA. With
regard to Germany, the G-BA is the supreme decision-
making body; however, the G-BA does not conduct
economic evaluations requiring an ICER for informing
coverage decisions except for those few cases where
there is a disagreement between the company and the
insurer, the G-BA. Similar to Germany, France has a
HTA agency that applies an evaluation process based
on evidence, not comparative cost effectiveness.
We found a significant correlation in which the RAI
decreased as the proportion of pharmaceutical expenditure
among total health care expenditure increased (ρ = −0.65,
P = 0.04) (Table 5) (Figure 2). The simple price of the drug
(P = 0.24), GDP (P = 0.19), and the proportion of healthcare
expenditure among GDP (P = 0.81) did not relate to RAI
significantly. Regarding the pattern of reimbursement status
(Figure 1), we tried to group countries into those with
similar patterns: A) UK and Sweden; B) Australia, Canada,
Taiwan, and Korea; C) Germany, Japan, France, and the
US. However, we did not find any correlation betweenr each drug indication in increasing order
ICER ( in US$)*
17,314
29,591















: 1st line with platinum-based chemotherapy 261,767
430,000‡
for Health and Clinical Excellence in United Kingdom (costs are expressed in
(Canadian $1 equals US $0.98) http://www.pbs.gov.au/info/industry/listing/
7.
Figure 1 Clustering of countries according to the pattern of reimbursement status. The color green is used to show that the indication is
reimbursed in a given country, and the color red signifies the indications that are not reimbursed. Each indication is sorted according to its ICER,
from the lowest (on top) to highest (on bottom).
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date of implementation of HTA systems, and other pa-
rameters in Table 5 (unpublished data).
Discussion
The present study shows that reimbursement policies
for anti-cancer drugs vary among countries even though
they rely on the same clinical evidence of those drugs.
Although most counties have adopted evidence-based
HTA programs to estimate the cost-effectiveness of
anti-cancer drugs, each HTA suggests different recom-
mendations. Overall, there was a strong correlation of
reimbursements in indications with lower ICERs.
Among the many factors that might influence reimburse-
ment policies, we focused on ICER, a surrogate index for
cost-effectiveness, because the ICER is regarded as well-
established evidence for basing resource allocation deci-
sions [30]. As healthcare costs continue to rise, recent
clinical trials have tried to integrate ICER into their
methods to provide further evidence of potential benefits
along with clinical efficacy [36]. Therefore, the decision to
place emphasis on ICER seemed to be a rational approach
for analyzing the diverse patterns of reimbursement
decisions.
We tried to collect ICER data from each country and
compare them, but most countries did not disclose reim-
bursement policies and related data. The UK, Australia,
Canada, and Sweden apply Cost-Effectiveness criteria in afairly rigorous way; on the other hand, France and
Germany measure the added clinical value on a 5-point
scale, which is then used as a guide for price negotiations.
France and Germany do not calculate the ICER at all, and
in this sense, the HTA agencies in France and Germany
do not conduct economic evaluations for informing reim-
bursement. The UK and Australia do the most thorough
job of establishing an ICER database online. Thus, ICER
data from NICE (UK) or PBAC (Australia) were retrieved.
In our study, the representative ICER data from NICE
were used as the standard for comparison instead of using
ICER data from different sources. However, the ICER
estimates might vary between countries depending on
which current practice is being used as a control, and
on assumptions about survival estimates for a new regi-
men. In addition, utilities for estimating incremental
health gain have national differences in their weighting
[37]. Thus, other determinants such as controls, real
world effectiveness estimates, unit costs, resource use
patterns, patient preferences, and the threshold might
account for differences in the ICERs and each country’s
respective reimbursement decisions. For the reasons men-
tioned above, there are inherent limitations to extrapolat-
ing NICE’s ICER values [6]. Furthermore, because the RAI
was calculated based on the ICERs mainly retrieved from
NICE (UK), the ranking reflects how well each country
adheres to NICE’s method of evaluating cost-effectiveness.
By using this standard, there is an inherent assumption
Table 4 Reimbursement adequacy index and social health insurance system
UK Canada Australia Sweden France* Japan Korea Taiwan Germany*
Reimbursement
adequacy index
0.79 0.68 0.63 0.58 0.58 0.58 0.53 0.53 0.47







100% General tax 33% General tax +43%
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Table 5 Health expenditure of each country
UK Canada Australia Sweden France Japan Korea Taiwan Germany
GDP per capita in US$ (2009) 34397 37773 39833 37255 33785 32061 26881 32214* 35643
Total expenditure on health (TEH), % of GDP (2009) 9.8 11.4 9.1 9.9 11.7 9.5 6.9 6.4* 11.7
Public expenditure on health, % of TEH (2009) 83.4 70.9 68.5 81.5 76.9 80.5 58.2 26.6* 76.9
Out-of-pocket expenditure (households) on health, % of TEH
(2009)
9.1 14.2 18.6 16.4 7.4 16 32.4 38.1* 13
Pharmaceutical expenditure and other medical non-durables, %
of TEH (2009)
11.8* 17 14.7 12.7 16.1 20.8 22.5 25* 14.9
Life expectancy of both sexes at birth in years (2009) 80.4 80.8* 81.6 81.4 81.1 83 80.4 79* 80.3
Abbreviations: GDP gross domestic product, UK United Kingdom, US United States.
Source: OECD website (except Taiwan) from http://stats.oecd.org/Index.aspx?DataSetCode=SHA.
For Taiwan, refers to 2012, Vol.3 , No1.
*When the data for 2009 was not available, the relevant data from 2008 was used.
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cisions and at the same time, the UK inevitably obtains
the highest RAI according to our method. This is by far
the greatest weakness of the analysis.
We found that indications with high cost-effectiveness
values (lower ICERs) were more likely to be reimbursed,
which suggests that each country considers cost-effect-
iveness in addition to clinical efficacy when deciding the
reimbursement of a certain drug. Given the finite financial
resources and rising costs of anti-cancer drugs, each coun-
try must be economical when deciding reimbursement
policies for each anti-cancer drug. Cheema et al. docu-
mented international variability in the ability to access
cancer drugs by measuring the number of licensed indica-
tions reimbursed by public payers [13]. However, they did
not go so far as to compare the pattern of reimbursement
decisions using a mathematical algorithm to systematicallyFigure 2 Proportion of total expenditure on health. Countries are arran
score (higher scores on the left and lower scores on the right).analyze a country’s efficiency in making cost-effective
coverage decisions with regard to ICER. Although the
findings of our study may have been expected, our
study attempts to compare reimbursement policies of
different countries with regard to cost-effectiveness by
using a systematic approach of calculating RAI.
We tried to cluster the countries according to the pat-
tern of reimbursement using microarray analysis methods
(Figure 1). However, we could not find any correlation
between clustering results and other indices, including
the RAI, government dependency on HTA, and other
parameters. This suggests that the reimbursement deci-
sion derived from estimates of cost-effectiveness cannot
be explained by one index alone.
There are many other factors that influence the decision
of authorities to fund certain drugs besides the ICER: the
patient’s demographics (i.e. drugs with higher ICERs tendged according to their respective reimbursement adequacy index
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cancer), the availability of alternative treatments, and the
consideration of new drugs with its impact on the juris-
diction’s healthcare budget. Undoubtedly, the decision
to approve a new drug is multifaceted and multifactorial.
Nevertheless, our findings show that the cost-effectiveness
is taken into prime consideration in many countries (espe-
cially countries which have adopted HTA since the
1990’s).
We introduced the concept of RAI to estimate how
efficiently each country decides to reimburse anti-cancer
drugs. Our study found an interesting relationship be-
tween RAI scores and social health insurance systems.
Specifically, the four countries that had high RAI scores,
UK, Canada, Australia, and Sweden have health systems
that are financed by general taxation. Additionally, coun-
tries with health care systems that are financed by general
taxation have operated HTA longer than those that are
financed by premium. This shows that countries with a
health system financed by general taxation are more likely
to consider the cost-effectiveness of certain anti-cancer
drugs. Considering the fact that no health insurance
system can cover every medical intervention despite
the clinical benefit, our findings reflect the realities of
current health systems.
Faden et al., who had a similar point of view, com-
pared the UK and US experiences with expensive cancer
drugs, and found that the UK system is fairer and better
structured than the US system when dealing with difficult
decisions about expensive end-of-life cancer drugs [38].
They emphasized the role of NICE when facing dilemmas
for competing clinical or cost-effectiveness of cancer
drugs, which supports our findings.
Our study had other limitations. First, the reimburse-
ment status may not be representative of real-world situa-
tions. Some cancer drugs are supported by other sources
of funding regardless of HTA recommendations. For ex-
ample, the Cancer Drug Fund in the UK supports some
indications that go against the policies by NICE, although
these are not national decisions. Second, the selection
of study countries and drug indications are inherent to
selection bias. Given the vast number of novel molecu-
lar targeted anti-cancer drugs available in the market of
the ten countries, it was challenging to select drugs and
their indications in a systemic way with clear selection
criteria. Furthermore, because the reimbursement decision
and the year of reimbursement were found using internet
searches, it was very challenging to find reliable informa-
tion for the purpose of our study. Third, the representative
ICER we presented may not perfectly reflect the current
appraisal of each country because of the aforementioned
reasons. Lastly, the threshold determined to be cost-
effective (ICERs being less than three times a country’s
GDP per capita) is arbitrary to use as a measure of costeffectiveness irrespective of the country’s health expend-
iture as a proportion of GDP; for example, the presence of
a functional generics market would increase the product-
ivity of the system with regard to branded drugs. Recent
empirical research in the UK showed that the threshold
is likely to be half the country’s GDP per capita [39].
However, despite these limitations, we tried to get the
gist using the best available evidence.
Conclusion
Although reimbursement policies for anti-cancer drugs
vary among countries, we found a strong correlation of
reimbursements favoring indications with lower ICERs.
Countries that have health systems financed by general
taxation adopt cost-effectiveness as evidenced by health-
care resource allocation.
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